Dengvaxia's post-launch plight reflects the difficulties of launching a vaccine. Is this a harbinger for future vaccine-marketing efforts?
The FDA approves J&J psoriasis drug; PARP inhibitors are not cost-effective, ICER says; Verily releases mosquitoes to combat Zika
Trump administration considers outcomes-based approach to lower drug prices; Sanofi to acquire vaccines biotech; Nestle partners with Enterome to develop microbiome-based diagnostics
Researchers test Zika vaccine; Aetna contacts doctors who prescribe high rates of opioids; half of pediatric trials are never published or completed
IBM to help analyze data about the spread of Zika; Grassley to investigate Part D program; Lilly CEO to retire